The former GlaxoSmithKline property in King of Prussia has added University of Pennsylvania’s gene therapy program as a new tenant, writes Jacob Adelman for The Philadelphia Inquirer.
Penn Medicine’s rapidly-growing unit has signed a 150,000-square-foot lease at the property and will use the space for part of its expanding research into genetic medicines for rare diseases. These include extremely rare diseases also known as orphan diseases and infectious diseases such as COVID-19.
The lease is a boon to J. Brian O’Neill, a local developer who has been promoting the former pharmaceutical plant as part of Discovery Labs, a network of lab and office buildings occupied by life-science tenants.
Penn required a large amount of lab space with high ceilings, advanced ventilation, and other requirements that only the former drug plant could meet. The university needed the space as soon as possible and it needed it in the Philadelphia region.
“If you want to do a lot of research fast, fast, fast,” said Hether Smith of commercial brokerage Savills, “the only real existing lab space right now is that former GSK space.”
Read more about the property in The Philadelphia Inquirer.